MCO Membrane Efficiency in Septic Shock Patients

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2017

Primary Completion Date

February 21, 2020

Study Completion Date

January 31, 2021

Conditions
Septic ShockAcute Kidney Injury
Interventions
DEVICE

Ultraflux® EMiC®2

Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout

Trial Locations (1)

27000

Fiorenza Ferrari, Pavia

All Listed Sponsors
collaborator

International Renal Research Institute Vicenza

OTHER

collaborator

University of Giessen

OTHER

lead

Fiorenza Ferrari

OTHER

NCT04834921 - MCO Membrane Efficiency in Septic Shock Patients | Biotech Hunter | Biotech Hunter